Degrasyn (WP1130)

Degrasyn (WP1130) is a selective deubiquitinase (DUB: USP5, UCH-L1, USP9x, USP14, and UCH37) inhibitor and also suppresses Bcr/Abl, also a JAK2 transducer (without affecting 20S proteasome) and activator of transcription (STAT). Degrasyn (WP1130) induces apoptosis and blocks autophagy.

Degrasyn (WP1130)化学構造

CAS No. 856243-80-6

サイズ 価格(税別) 在庫状況
JPY 30200 国内在庫あり
JPY 163000 国内在庫あり
JPY 332300 国内在庫あり

代表番号: 045-509-1970|電子メール:[email protected]
よく尋ねられる質問

文献中Selleckの製品使用例(42)

製品安全説明書

現在のバッチを見る: 純度: 99.97%
99.97

Degrasyn (WP1130)関連製品

シグナル伝達経路

Bcr-Abl阻害剤の選択性比較

Cell Data

Cell Lines Assay Type Concentration Incubation Time 活性情報 PMID
Z138 Function assay 1.25 to 5 uM 4 hrs Inhibition of Usp9x in human Z138 cells using HA-Ub vinyl-sulfone as substrate at 1.25 to 5 uM after 4 hrs by immunoblotting analysis 24457091
Z138 Function assay 1.25 to 5 uM 4 hrs Inhibition of Usp9x in human Z138 cells at 1.25 to 5 uM incubated for 4 hrs by SDS-PAGE and immunoblotting ChEMBL
Z138 Function assay 1.25 to 5 uM 4 hrs Inhibition of Usp9x in human Z138 cells assessed as reduction in Mcl-1 protein level at 1.25 to 5 uM incubated for 4 hrs by SDS-PAGE and immunoblotting ChEMBL
Z138 Function assay 1.25 to 5 uM 4 hrs Inhibition of Usp9x in human Z138 cells at 1.25 to 5 uM incubated for 4 hrs by immunoblotting analysis ChEMBL
Z138 Function assay 1.25 to 5 uM 4 hrs Inhibition of Usp9x in human Z138 cells assessed as reduction in Mcl1 protein levels at 1.25 to 5 uM incubated for 4 hrs by immunoblotting analysis ChEMBL
A375 Cytotoxicity assay 72 hrs Cytotoxicity against human A375 cells after 72 hrs by MTT assay, IC50=1.7μM 24457091
OCI-My4 Antitumor assay 24 to 72 hrs Antitumor activity against human OCI-My4 cells after 24 to 72 hrs by MTT assay, IC50=1.5μM 22036213
U266 Antitumor assay 24 to 72 hrs Antitumor activity against human U266 cells after 24 to 72 hrs by MTT assay, IC50=1.3μM 22036213
MM1S Cytotoxicity assay 72 hrs Cytotoxicity against human MM1S cells after 72 hrs by MTT assay, IC50=1.2μM 24457091
MM1 Antitumor assay 24 to 72 hrs Antitumor activity against human MM1 cells after 24 to 72 hrs by MTT assay, IC50=1μM 22036213
Mino Cytotoxicity assay 72 hrs Cytotoxicity against human Mino cells after 72 hrs by MTT assay, IC50=0.8μM 24457091
K562 Cytotoxicity assay 72 hrs Cytotoxicity against human K562 cells after 72 hrs by MTT assay, IC50=2.4μM 24457091
Z138 Function assay 1 hr Inhibition of UCH-L1 in human Z138 cells after 1 hr by immunoblotting analysis, IC50=3μM 23791076
Z138 Function assay 1 hr Inhibition of USP9x in human Z138 cells after 1 hr by immunoblotting analysis, IC50=3μM 23791076
Z138 Function assay 1 hr Inhibition of USP5 in human Z138 cells after 1 hr by immunoblotting analysis, IC50=3μM 23791076
他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

生物活性

製品説明 Degrasyn (WP1130) is a selective deubiquitinase (DUB: USP5, UCH-L1, USP9x, USP14, and UCH37) inhibitor and also suppresses Bcr/Abl, also a JAK2 transducer (without affecting 20S proteasome) and activator of transcription (STAT). Degrasyn (WP1130) induces apoptosis and blocks autophagy.
特性 WP1130 has an advantage over imatinib mesylate in that its activity is not inhibited by a variety of Abl kinase mutations, including T315I.
Targets
DUB [1]
(Cell-free assay)
Bcr-Abl [1]
(Cell-free assay)
1.8 μM
In Vitro
In vitro In addition to inducing rapid down-regulation of Bcr/Abl without affecting Bcr or c-Abl, WP1130 also regulates the stability of Jak2 and c-Myc without affecting other kinases (HER1, HER2, c-Kit, FAK, ERK1, ERK2, Akt, Btk, Src and Src-related kinases) or transcription factors (wild-type p53, STAT1, STAT3, STAT5, c-Jun, NF-κB, and Max). Unlike adaphostin and Trisenox, WP1130 induces down-regulation of Bcr/Abl within 60 minutes. WP1130 is more effective in inducing apoptosis of myeloid and lymphoid tumor cells with IC50 of ~0.5-2.5 μM compared with normal CD34+ hematopoietic precursors, dermal fibroblasts, or endothelial cells with IC50 of ~5-10 μM. WP1130 (5 μM) specifically and rapidly down-regulates both wild-type and T315I mutant Bcr/Abl protein without affecting bcr/abl gene expression or engaging the proteasomal degradation pathway in chronic myelogenous leukemia (CML) cells, accompanied by induction of apoptosis. WP1130 is more effective in reducing leukemic cell colony formation compared with normal progenitor cells, and effective against primary leukemic cells harboring the T315I mutation. [1] WP1130 induces rapid proteasomal-dependent degradation of c-Myc protein in MM-1 multiple myeloma and other tumor cell lines, correlated with tumor growth inhibition. [2] Unlike AG490, WP1130 acts as a partly selective deubiquitinase (DUB) inhibitor to induce a rapid and marked accumulation of polyubiquitinated (K48/K63-linked) proteins into juxtanuclear aggresomes without affecting proteasome activity. WP1130 (5 μM) directly inhibits DUB activity of USP9x, USP5, USP14, UCH-L1, and UCH37, but not UCH-L3, resulting in downregulation of antiapoptotic and upregulation of proapoptotic proteins, such as MCL-1 and p53. [3]
細胞実験 細胞株 BV173, BV173R, K562, and BaF/3
濃度 Dissolved in DMSO, final concentrations ~10 μM
反応時間 72 hours
実験の流れ Cells are treated with increasing concentrations of WP1130 (0.08-10 μM) in 96-well plates. Plates are incubated at 37 °C for 72 hours, after which 20 μL of MTT reagent is added, and the plates are incubated at 37 °C for another 2 hours. Cells are lysed with 100 μL lysis buffer (20% sodium dodecyl sulfate [SDS] in 50% N, N-dimethylformamide adjusted to pH 4.7 with 80% acetic acid and 1 M hydrochloric acid; final concentration of acetic acid is 2.5% and hydrochloric acid is 2.5%) and incubated for 6 hours. The optical density of each sample at 570 nm is determined with a SPECTRA MAX M2 plate reader.
In Vivo
In Vivo Administration of WP1130 inhibits the growth of K562 tumors as well as both wildtype Bcr/Abl and T315I mutant Bcr/Abl-expressing BaF/3 cells transplanted into nude mice. [1] Consistent with the down-regulation of c-Myc, WP1130 displays potent inhibitory activity against A375 melanoma tumors established in nude mice. [2]
動物実験 動物モデル Swiss Nu/Nu mice transplanted with K562 tumor cells, BaF/3wt cells, or BaF/3/T315I cells
投与量 ~40 mg/kg every other day
投与経路 Injected intraperitoneally

化学情報

分子量 384.27 化学式

C19H18BrN3O

CAS No. 856243-80-6 SDF Download Degrasyn (WP1130) SDFをダウンロードする
Smiles CCCC(C1=CC=CC=C1)NC(=O)C(=CC2=NC(=CC=C2)Br)C#N
保管

In vitro
Batch:

DMSO : 77 mg/mL ( (200.37 mM); 吸湿したDMSOは溶解度を減少させます。新しいDMSOをご使用ください。)

Ethanol : 50 mg/mL

Water : Insoluble

モル濃度計算器

in vivo
Batch:

Add solvents to the product individually and in order.

投与溶液組成計算機

実験計算

モル濃度計算器

質量 濃度 体積 分子量

投与溶液組成計算機(クリア溶液)

ステップ1:実験データを入力してください。(実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します)

mg/kg g μL

ステップ2:投与溶媒の組成を入力してください。(ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください)

% DMSO % % Tween 80 % ddH2O
%DMSO %

計算結果:

投与溶媒濃度: mg/ml;

DMSOストック溶液調製方法: mg 試薬を μL DMSOに溶解する(濃度 mg/mL, 注:濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。 )

投与溶媒調製方法:Take μL DMSOストック溶液に μL PEG300,を加え、完全溶解後μL Tween 80,を加えて完全溶解させた後 μL ddH2O,を加え完全に溶解させます。

投与溶媒調製方法:μL DMSOストック溶液に μL Corn oil,を加え、完全溶解。

注意:1.ストック溶液に沈殿、混濁などがないことをご確認ください;
2.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

大学・企業名を記入してください
名前を記入してください
電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
お問い合わせ内容をご入力ください
Tags: Degrasyn (WP1130)を買う | Degrasyn (WP1130) ic50 | Degrasyn (WP1130)供給者 | Degrasyn (WP1130)を購入する | Degrasyn (WP1130)費用 | Degrasyn (WP1130)生産者 | オーダーDegrasyn (WP1130) | Degrasyn (WP1130)化学構造 | Degrasyn (WP1130)分子量 | Degrasyn (WP1130)代理店